Usefulness of C-reactive protein/albumin ratio as a predictor of new-onset atrial fibrillation in SARS-COV-2.
Saban KelesogluYucel YilmazEyup OzkanBekir CalapkorurZehra B DursunAysegul Ulu-KilicDeniz ElçikPublished in: Biomarkers in medicine (2021)
Aim: To investigate whether C-reactive protein/albumin ratio (CAR) has an association with new onset atrial fibrillation (NOAF) in SARS-CoV-2. Materials & methods: This study included 782 patients with SARS-CoV-2 infection, who were hospitalized in Turkey. The end point of the study was an occurrence of NOAF. Results: NOAF was identified in 41 patients (5.2%). Subjects who developed NOAF had a higher CAR compared with those who did not develop NOAF (p < 0.001). In the multivariate logistic regression analysis the CAR (odds ratio = 2.879; 95% CI: 1.063-7.793; p = 0.037) was an independent predictor of NOAF. Conclusion: A high level of CAR in blood samples is associated with an increased risk of developing NOAF in SARS-CoV-2.
Keyphrases
- sars cov
- atrial fibrillation
- respiratory syndrome coronavirus
- end stage renal disease
- newly diagnosed
- heart failure
- ejection fraction
- left atrial appendage
- catheter ablation
- direct oral anticoagulants
- percutaneous coronary intervention
- prognostic factors
- oral anticoagulants
- acute coronary syndrome
- coronavirus disease
- peritoneal dialysis
- venous thromboembolism